High-dose omalizumab use in patients with chronic spontaneous urticaria

J Allergy Clin Immunol Pract. 2020 Apr;8(4):1426-1427.e1. doi: 10.1016/j.jaip.2019.10.018. Epub 2019 Oct 31.

Authors

Mehran Alizadeh Aghdam¹, Fenne van den Broek², Feiko Rijken², Andre Cornelis Knulst², Heike Röckmann²

Affiliations

¹ Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Electronic address: [email protected].
² Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

PMID: 31678293
DOI: 10.1016/j.jaip.2019.10.018

No abstract available

MeSH terms

Anti-Allergic Agents* / therapeutic use
Chronic Disease
Chronic Urticaria*
Humans
Omalizumab / therapeutic use
Treatment Outcome
Urticaria* / drug therapy

Substances

Anti-Allergic Agents
Omalizumab